# Imatinib Mesylate in Treating Patients With Myelofibrosis

> **NCT00039416** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Essential Thrombocythemia
- Polycythemia Vera
- Primary Myelofibrosis

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00039416
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039416, "Imatinib Mesylate in Treating Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00039416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*